These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 7502157)

  • 1. [Molecular bases of cancer immunology].
    Barrera-Rodríguez R; Peralta-Zaragoza O; Madrid-Marina V
    Salud Publica Mex; 1995; 37(4):344-53. PubMed ID: 7502157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer immunogene therapy.
    Yoshizawa H; Kagamu H; Gejyo F
    Arch Immunol Ther Exp (Warsz); 2001; 49(5):337-43. PubMed ID: 11798131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor escape from immune surveillance.
    Costello RT; Gastaut JA; Olive D
    Arch Immunol Ther Exp (Warsz); 1999; 47(2):83-8. PubMed ID: 10202560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor rejection antigens and tumor specific cytotoxic T lymphocytes.
    Toes RE; Offringa R; Feltkamp MC; Visseren MJ; Schoenberger SP; Melief CJ; Kast WM
    Behring Inst Mitt; 1994 Jul; (94):72-86. PubMed ID: 7998917
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospect on cancer immunology.
    Kobayashi H
    Hokkaido Igaku Zasshi; 1979 Nov; 54(6):549-77. PubMed ID: 397163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor immunity and immunotherapy.
    Boura P; Kountouras J; Lygidakis NJ
    Hepatogastroenterology; 2001; 48(40):1040-4. PubMed ID: 11490795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutics targeting tumor immune escape: towards the development of new generation anticancer vaccines.
    Mocellin S; Nitti D
    Med Res Rev; 2008 May; 28(3):413-44. PubMed ID: 17694549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cancer immunotherapy: immunologic bases, reality and hopes].
    Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F
    Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine therapy for cancer: fact or fiction?
    Odunsi K; Lele S; Savalgi R
    Surg Technol Int; 2004; 13():39-47. PubMed ID: 15744673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor vaccine: current trends in antigen specific immunotherapy.
    Baral R
    Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
    Jinushi M; Hodi FS; Dranoff G
    Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting costimulatory pathways for tumor immunotherapy.
    Ward RC; Kaufman HL
    Int Rev Immunol; 2007; 26(3-4):161-96. PubMed ID: 17558743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The allogeneic response and tumor immunity.
    Fabre JW
    Nat Med; 2001 Jun; 7(6):649-52. PubMed ID: 11385492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.